Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Access to Study Drug for Pediatric Participants Completing Gilead HIV Treatment Studies
NCT06337032Phase 4Recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4 trial of bictegravir, emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Aug 2024; status: recruiting.
02
Drugs
bictegraviremtricitabinetenofovir alafenamideelvitegravircobicistat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06337032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337032.